US FDA Approves Trodelvy for Metastatic Triple-Negative Breast Cancer

The U.S. Food and Drug Administration approved Trodelvy as a first-line treatment for metastatic triple-negative breast cancer in April 2024 [2, 3].

This approval provides a critical new tool for patients fighting one of the most aggressive forms of breast cancer. Because triple-negative breast cancer is historically difficult to treat, the introduction of a new primary therapy represents a significant shift in the standard of care.

Developed by Gilead Sciences, Inc., Trodelvy (sacituzumab govitecan) is now authorized for use both as a monotherapy and in combination with Keytruda [1, 2]. The FDA's decision allows physicians to utilize the drug as a first-line defense rather than reserving it for later stages of the disease [2, 3].

Medical experts said this is the first new backbone therapy option for metastatic triple-negative breast cancer in more than two decades [1, 2]. The lack of new foundational treatments for this specific cancer subtype has long been a challenge for oncologists seeking to improve patient outcomes.

Triple-negative breast cancer lacks the three most common receptors, estrogen, progesterone, and HER2, which typically make breast cancer easier to target with hormone therapy ^[1]. By introducing Trodelvy as a first-line option, the FDA aims to offer a more effective starting point for patients facing this diagnosis [1, 2].

The approval process was finalized at the FDA headquarters in Silver Spring, Maryland [2, 3]. The agency's decision follows a review of the drug's efficacy in treating metastatic cases where the cancer has spread to other parts of the body ^[2].